Sökning: id:"swepub:oai:gup.ub.gu.se/296636" >
Implementation of s...
Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants
-
- Fu, Michael, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden
-
- Vedin, Ola (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi,Uppsala Univ, Sweden
-
- Svennblad, Bodil (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Uppsala Univ, Sweden
-
visa fler...
-
- Lampa, Erik, 1977- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Uppsala Univ, Sweden
-
- Johansson, D. (författare)
- Novartis Sweden AB, Stockholm, Sweden
-
- Dahlström, Ulf (författare)
- Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US
-
- Lindmark, Krister (författare)
- Umeå universitet,Kardiologi,Umeå Univ, Dept Publ Hlth & Clin Med, Heart Ctr, Umeå, Sweden
-
- Vasko, P. (författare)
- Cent Hosp Växjö, Växjö, Sweden
-
- Lundberg, A. (författare)
- Novartis Sweden AB, Stockholm, Sweden
-
- Costa-Scharplatz, M. (författare)
- Novartis Sweden AB, Stockholm, Sweden
-
- Lund, L. H. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2020-09-03
- 2020
- Engelska.
-
Ingår i: Esc Heart Failure. - : Wiley. - 2055-5822.
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://doi.org/10.1...
-
https://umu.diva-por... (primary) (Raw object)
-
https://uu.diva-port... (primary) (Raw object)
-
https://liu.diva-por... (primary) (Raw object)
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims The aim of this study is to study the introduction of sacubitril/valsartan (sac/val) in Sweden with regards to regional differences, clinical characteristics, titration patterns, and determinants of use and discontinuation. Methods and results A national cohort of heart failure was defined from the Swedish Prescribed Drug Register and National Patient Register. A subcohort with additional data from the Swedish Heart Failure Registry (SwedeHF) was also studied. Cohorts were subdivided as per sac/val prescription and registration in SwedeHF. Median sac/val prescription rate was 20 per 100 000 inhabitants. Between April 2016 and December 2017, we identified 2037 patients with >= 1 sac/val prescription, of which 1144 (56%) were registered in SwedeHF. Overall, patients prescribed with sac/val were younger, more frequently male, and had less prior cardiovascular disease than non-sac/val patients. In SwedeHF subcohort, patients prescribed with sac/val had lower ejection fraction. Overall, younger age [hazard ratio 2.81 (95% confidence interval 2.45-3.22)], registration in SwedeHF [1.97 (1.83-2.12)], male gender [1.50 (1.37-1.64)], ischaemic heart disease [1.50 (1.39-1.62)], lower left ventricular ejection fraction [3.06 (2.18-4.31)], and New York Heart Association IV [1.50 (1.22-1.84)] were predictors for sac/val use. As initiation dose in the sac/val cohort, 38% received 24/26 mg, 54% 49/51 mg, and 9% 97/103 mg. Up-titration to the target dose was achieved in 57% of the overall cohort over a median follow-up of 6 months. The estimated treatment persistence for any dose at 360 days was 82%. Conclusions Implementation of sac/val in Sweden was slow and varied five-fold across different regions; younger age, male, SwedeHF registration, and ischaemic heart disease were among the independent predictors of receiving sac/val. Overall, treatment persistence and tolerability was high.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Samhällsfarmaci och klinisk farmaci (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Social and Clinical Pharmacy (hsv//eng)
Nyckelord
- Sacubitril
- valsartan
- Sweden
- Real-world
- Registry
- heart-failure
- guidelines
- Cardiovascular System & Cardiology
- Sacubitril
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Fu, Michael, 196 ...
-
Vedin, Ola
-
Svennblad, Bodil
-
Lampa, Erik, 197 ...
-
Johansson, D.
-
Dahlström, Ulf
-
visa fler...
-
Lindmark, Kriste ...
-
Vasko, P.
-
Lundberg, A.
-
Costa-Scharplatz ...
-
Lund, L. H.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Samhällsfarmaci ...
- Artiklar i publikationen
-
Esc Heart Failur ...
- Av lärosätet
-
Göteborgs universitet
-
Umeå universitet
-
Uppsala universitet
-
Linköpings universitet
-
Karolinska Institutet